-
5 days ago | 
onclive.com | Ashling Wahner
Lutetium Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) plus hormone therapy yielded a statistically significant and clinically meaningful radiographic progression-free survival (rPFS) benefit vs hormone therapy alone in patients with prostate-specific membrane antigen (PSMA)–positive metastatic hormone-sensitive prostate cancer (mHSPC), meeting the primary end point of the phase 3 PSMAddition trial (NCT04720157).1 Topline findings from a prespecified interim analysis of the...
-
1 week ago | 
oncnursingnews.com | Ashling Wahner
May 28, 2025Fact checked by SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.
-
1 week ago | 
oncnursingnews.com | Ashling Wahner
May 28, 2025Fact checked by SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.
-
2 weeks ago | 
oncnursingnews.com | Ashling Wahner
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously (8 to 0) against the risk-benefit profile of talazoparib (Talzenna) combined with enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) lacking homologous recombination repair (HRR) mutations.1This decision was based on findings from the phase 3 TALAPRO-2 trial (NCT03395197), and the ODAC's decision was shared in a meeting hosted by the regulatory agency.
-
2 weeks ago | 
oncnursingnews.com | Ashling Wahner
Ribociclib (Kisqali) combined with endocrine therapy produced low but comparable pathologic complete response (pCR) rates to standard chemotherapy in patients with intermediate-risk, hormone receptor (HR)–positive, HER2-negative early breast cancer, according to data from the neoadjuvant cohort of the phase 3 WSG ADAPTcycle trial (NCT04055493).1 Data presented at the 2025 ESMO Breast Congress showed that at a median treatment duration of 5.7 months (range, 0.7-10.5), 5.7% of patients who...
-
2 weeks ago | 
onclive.com | Ashling Wahner
The early-stage triple-negative breast cancer (TNBC) research paradigm contains several clinical trials that may refine or replace standard-of-care treatment backbones to personalize therapy and improve treatment tolerability, according to Alexis LeVee, MD. “Lots of trials in the early TNBC setting are ongoing,” LeVee said in an interview with OncLive®.
-
3 weeks ago | 
onclive.com | Ashling Wahner
Ribociclib (Kisqali) plus endocrine therapy generated low pathologic complete response (pCR) rates that were similar to those seen with standard-of-care (SOC) chemotherapy in patients with intermediate-risk hormone receptor (HR)–positive, HER2-negative early breast cancer, according to findings from the neoadjuvant cohort of the phase 3 WSG ADAPTcycle trial (NCT04055493).1 Data presented at the 2025 ESMO Breast Congress showed that at a median treatment duration of 5.7 months (range,...
-
3 weeks ago | 
onclive.com | Ashling Wahner
Retifanlimab-dlwr (Zynyz) is approved with carboplatin and paclitaxel for first-line treatment of inoperable or metastatic SCAC. Retifanlimab monotherapy is approved for SCAC patients with progression on or intolerance to platinum-based chemotherapy. Approvals are based on phase 3 POD1UM-303/InterAACT2 and phase 2 POD1UM-202 trial results.
-
3 weeks ago | 
onclive.com | Ashling Wahner
Pembrolizumab (Keytruda) plus paclitaxel with or without bevacizumab (Avastin) significantly improved progression-free survival (PFS) vs placebo plus chemotherapy with or without bevacizumab in patients with platinum-resistant recurrent ovarian cancer regardless of PD-L1 status, meeting the primary end point of the phase 3 KEYNOTE-B96 trial/ENGOT-ov65 trial (NCT05116189).1 Data from the prespecified interim analysis of the trial, which was conducted by an independent data monitoring...
-
3 weeks ago | 
targetedonc.com | Ashling Wahner
Updated results from the phase 3 ENGOT-EN6-NSGO/GOG3031/RUBY study (NCT03981796) show that adding dostarlimab-gxly (Jemperli) to standard chemotherapy significantly improves the median duration of response (DOR) by 4.4 months compared with chemotherapy alone in patients with primary advanced or recurrent endometrial cancer.
